Suppr超能文献

3,5-二酰基-2,4-二烷基吡啶衍生物作为选择性A3腺苷受体拮抗剂的构效关系及分子模拟

Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.

作者信息

Li A H, Moro S, Melman N, Ji X D, Jacobson K A

机构信息

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.

出版信息

J Med Chem. 1998 Aug 13;41(17):3186-201. doi: 10.1021/jm980093j.

Abstract

The structure-activity relationships of 6-phenyl-1,4-dihydropyridine derivatives as selective antagonists at human A3 adenosine receptors have been explored (Jiang et al. J. Med. Chem. 1997, 39, 4667-4675). In the present study, related pyridine derivatives have been synthesized and tested for affinity at adenosine receptors in radioligand binding assays. Ki values in the nanomolar range were observed for certain 3,5-diacyl-2,4-dialkyl-6-phenylpyridine derivatives in displacement of [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)-5'-N-methylcarbamoyladenosine) at recombinant human A3 adenosine receptors. Selectivity for A3 adenosine receptors was determined vs radioligand binding at rat brain A1 and A2A receptors. Structure-activity relationships at various positions of the pyridine ring (the 3- and 5-acyl substituents and the 2- and 4-alkyl substituents) were probed. A 4-phenylethynyl group did not enhance A3 selectivity of pyridine derivatives, as it did for the 4-substituted dihydropyridines. At the 2- and 4-positions ethyl was favored over methyl. Also, unlike the dihydropyridines, a thioester group at the 3-position was favored over an ester for affinity at A3 adenosine receptors, and a 5-position benzyl ester decreased affinity. Small cycloalkyl groups at the 6-position of 4-phenylethynyl-1,4-dihydropyridines were favorable for high affinity at human A3 adenosine receptors, while in the pyridine series a 6-cyclopentyl group decreased affinity. 5-Ethyl 2, 4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate , 38, was highly potent at human A3 receptors, with a Ki value of 20 nM. A 4-propyl derivative, 39b, was selective and highly potent at both human and rat A3 receptors, with Ki values of 18.9 and 113 nM, respectively. A 6-(3-chlorophenyl) derivative, 44, displayed a Ki value of 7.94 nM at human A3 receptors and selectivity of 5200-fold. Molecular modeling, based on the steric and electrostatic alignment (SEAL) method, defined common pharmacophore elements for pyridine and dihydropyridine structures, e.g., the two ester groups and the 6-phenyl group. Moreover, a relationship between affinity and hydrophobicity was found for the pyridines.

摘要

6-苯基-1,4-二氢吡啶衍生物作为人A3腺苷受体选择性拮抗剂的构效关系已得到研究(Jiang等人,《药物化学杂志》,1997年,39卷,4667 - 4675页)。在本研究中,已合成了相关吡啶衍生物,并通过放射性配体结合试验检测其对腺苷受体的亲和力。在重组人A3腺苷受体上,某些3,5-二酰基-2,4-二烷基-6-苯基吡啶衍生物在置换[125I]AB - MECA(N6-(4-氨基-3-碘苄基)-5'-N-甲基氨基甲酰腺苷)时观察到纳摩尔范围内的Ki值。通过与大鼠脑A1和A2A受体的放射性配体结合测定,确定了对A3腺苷受体的选择性。研究了吡啶环不同位置(3-和5-酰基取代基以及2-和4-烷基取代基)的构效关系。4-苯乙炔基并未像对4-取代二氢吡啶那样增强吡啶衍生物的A3选择性。在2-和4-位,乙基比甲基更受青睐。此外,与二氢吡啶不同,3-位的硫酯基在A3腺苷受体亲和力方面比酯基更受青睐,而5-位的苄酯会降低亲和力。4-苯乙炔基-1,4-二氢吡啶6-位的小环烷基有利于与人A3腺苷受体的高亲和力,而在吡啶系列中,6-环戊基会降低亲和力。5-乙基2,4-二乙基-3-(乙硫基羰基)-6-苯基吡啶-5-羧酸酯(38)对人A3受体具有高效力,Ki值为20 nM。一种4-丙基衍生物(39b)对人和大鼠A3受体均具有选择性且高效力,Ki值分别为18.9和113 nM。一种6-(3-氯苯基)衍生物(44)在人A3受体上的Ki值为7.94 nM,选择性为5200倍。基于空间和静电排列(SEAL)方法的分子建模确定了吡啶和二氢吡啶结构的共同药效基团元素,例如两个酯基和6-苯基。此外,还发现了吡啶的亲和力与疏水性之间的关系。

相似文献

引用本文的文献

1
Adenosine A and A Receptors: Distinct Cardioprotection.
Drug Dev Res. 2001 Jan-Feb;52(1-2):366-378. doi: 10.1002/ddr.1136.
3
Selective modulation of epileptic tissue by an adenosine A receptor-activating drug.
Br J Pharmacol. 2024 Dec;181(24):5041-5061. doi: 10.1111/bph.17319. Epub 2024 Sep 19.
4
Assay-Dependent Inverse Agonism at the A Adenosine Receptor: When Neutral Is Not Neutral.
ACS Pharmacol Transl Sci. 2023 Aug 9;6(9):1266-1274. doi: 10.1021/acsptsci.3c00071. eCollection 2023 Sep 8.
5
Species dependence of A adenosine receptor pharmacology and function.
Purinergic Signal. 2023 Sep;19(3):523-550. doi: 10.1007/s11302-022-09910-1. Epub 2022 Dec 20.
6
Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.
Pharmacol Ther. 2022 Dec;240:108300. doi: 10.1016/j.pharmthera.2022.108300. Epub 2022 Oct 22.
8
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.
Pharmacol Rev. 2022 Apr;74(2):340-372. doi: 10.1124/pharmrev.121.000445.
9
Pharmacological characterization of DPTN and other selective A adenosine receptor antagonists.
Purinergic Signal. 2021 Dec;17(4):737-746. doi: 10.1007/s11302-021-09823-5. Epub 2021 Oct 28.
10
Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.
Mol Divers. 2022 Jun;26(3):1779-1821. doi: 10.1007/s11030-021-10257-9. Epub 2021 Jun 27.

本文引用的文献

1
Adenosine A3 receptors: novel ligands and paradoxical effects.
Trends Pharmacol Sci. 1998 May;19(5):184-91. doi: 10.1016/s0165-6147(98)01203-6.
2
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists.
Neuropharmacology. 1997 Sep;36(9):1157-65. doi: 10.1016/s0028-3908(97)00104-4.
3
Adenosine A3 receptor stimulation inhibits migration of human eosinophils.
J Leukoc Biol. 1997 Oct;62(4):465-8. doi: 10.1002/jlb.62.4.465.
8
Plasma and urinary metabolites of efonidipine hydrochloride in man.
Xenobiotica. 1996 Feb;26(2):229-39. doi: 10.3109/00498259609046703.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验